The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: A retrospective analysis

Diabetic Medicine

Volumn 29, Issue 8, 2012, Pages 1029-1035

  Pantalone, K M ^a   Kattan, M W ^b   Yu, C ^b   Wells, B J ^b   Arrigain, S ^b   Nutter, B ^b   Jain, A ^b   Atreja, A ^b   Zimmerman, R S ^b  

^a Summa Western Reserve Hospital Physicians Inc   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Diabetes; Metformin; Mortality; Sulfonylurea

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE PLUS METFORMIN; GLIPIZIDE PLUS METFORMIN; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLIPIZIDE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 84863992026     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2012.03577.x     Document Type: Article

References (28)

1. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
2. Olsson J, Lindberg G, Gottsater M, Lindwall K, Sjostrand A, Tisell A et al. Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 2000; 43: 558-560.
3. Fisman EZ, Tenenbaum A, Boyko V, Benderly M, Adler Y, Friedensohn A et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 2001; 24: 151-158.
4. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-2248.
5. Gulliford M, Latinovic R. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev 2004; 20: 239-245.
6. Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006; 49: 930-936.
7. Kahler KH, Rajan M, Rhoads GG, Safford MM, Demissie K, Lu SE et al. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration. Diabetes Care 2007; 30: 1689-1693.
8. Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care 2008; 31: 1672-1678.
9. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007; 30: 389-394.
10. Gribble FM, Reimann F. Sulphonylurea action revisited: the post-cloning era. Diabetologia 2003; 46: 875-891.
11. Evans JM, Ogston SA, Reimann F, Gribble FM, Morris AD, Pearson ER. No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: a cohort analysis. Diabetes Obes Metab 2008; 10: 350-352.
12. Song DK, Ashcroft FM. Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels. Br J Pharmacol 2001; 133: 193-199.
13. Tomai F, Crea F, Gaspardone A, Versaci F, De Paulis R, Penta de Peppo A et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 1994; 90: 700-705.
14. Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker KH et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999; 20: 439-446.
15. Flynn DM, Smith AH, Treadway JL, Levy CB, Soeller WC, Boettner WA et al. The sulfonylurea glipizide does not inhibit ischemic preconditioning in anesthetized rabbits. Cardiovasc Drugs Ther 2005; 19: 337-346.
16. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care 2010; 33: 1224-1229.
17. Zeller M, Danchin N, Simon D, Vahanian A, Lorgis L, Cottin Y et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab 2010; 95: 4993-5002.
18. Correia S, Carvalho C, Santos MS, Seica R, Oliveira CR, Moreira PI. Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview. Mini Rev Med Chem 2008; 8: 1343-1354.
19. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol 2009; 46: 145-154.
20. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281.
21. Horsdal HT, Johnsen SP, Sondergaard F, Jacobsen J, Thomsen RW, Schmitz O et al. Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study. Diabetes Metab Res Rev 2009; 25: 515-522.
22. Khalangot M, Tronko M, Kravchenko V, Kovtun V. Glibenclamide-related excess in total and cardiovascular mortality risks: Data from large Ukrainian observational cohort study. Diabetes Res Clin Pract 2009; 86: 247-253.
23. Monami M, Luzzi C, Lamanna C, Chiasserini V, Addante F, Desideri CM et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 2006; 22: 477-482.
24. Monami M, Marchionni N, Masotti G, Mannucci E. Effect of combined secretagogue/biguanide treatment on mortality in type 2 diabetic patients with and without ischemic heart disease. Int J Cardiol 2008; 126: 247-251.
25. Hoenig JM, Heisey DM. The Abuse of Power: The Pervasive Fallacy of Power Calculations for Data Analysis. The American Statistician 2001; 55: 19-24.
26. Snee RD. Validation of Regression Models: Methods and Examples. Technometrics 1977; 19: 415-428.
27. van der Heijden GJ, Donders AR, Stijnen T, Moons KG. Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: a clinical example. J Clin Epidemiol 2006; 59: 1102-1109.
28. Schafer JL. Multiple imputation: A primer. Stat Methods Med Res 1999; 8: 3-15.